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Inflammatory processes and tissue scarring are characteristic
features of chronic allograft nephropathy. Hepatocyte
growth factor (HGF) has beneficial effects on renal fibrosis
and it also ameliorates renal interstitial inflammation as it has
been recently described. Contrarily to protein administration,
intramuscular gene electrotransfer allows sustained release
of HGF. So, here we hypothesized that gene therapy with
human HGF would diminish the characteristic scarring of
chronic allograft nephropathy either by antagonizing tissue
fibrosis mechanisms or by reducing inflammation. Lewis rats
transplanted with cold preserved Fischer kidneys received
vehicle (NoHGF) or intramuscular plasmid DNA encoding HGF
plus electroporation either before transplantation (IniHGF,
early post-transplant cytoprotection of tubular cells) or 8/10
weeks after transplantation (DelHGF, delayed prevention of
chronic mechanisms). Serum creatinine and proteinuria were
measured every 4 weeks for 24 weeks. Grafts at 12 or 24
weeks were evaluated for glomerulosclerosis, fibrosis
inflammatory cells and mediators, cell regeneration and
tubulo-interstitial damage. Nontreated animals developed
renal insufficiency, progressive proteinuria and fibrosis
among other characteristic histological features of chronic
allograft nephropathy. Treatment with human HGF,
especially when delayed until the onset of fibrogenic
mechanisms, reduced renal failure and mortality, diminished
tubule-interstitial damage, induced cell regeneration,
decreased inflammation, NF-jB activation, and profibrotic
markers at 12 weeks and prevented late interstitial fibrosis
and glomerulosclerosis. The effectiveness of HGF-gene
therapy in the prevention of renal allograft scarring is related
with the halt of profibrotic inflammatory-induced
mechanisms.
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Hepatocyte growth factor (HGF) has multiple biological
activities in a wide variety of cells, including renal tubular
and endothelial.1 Its expression is upregulated at early stages
of chronic processes as a natural repair mechanism but
sustained injury throughout these processes results in the
overexpression of other growth factors that have antagonistic
effects to HGF. The equilibrium between HGF and
profibrotic factors is then imbalanced in favor of the latter,
thereby resulting in extracellular matrix accumulation and
progression to renal fibrosis.1,2 Protein HGF supply has
been shown to prevent the onset of renal scarring by
inhibiting the morphologic transformation of tubular
epithelial cells.3,4
Recently, it has been reported that HGF is a potent anti-
inflammatory cytokine that decreases the RNA expression of
tumor necrosis factor-a (TNF-a) and interferon-g (IFN-g),
two inflammatory cytokines5 and directly suppresses pro-
inflammatory membrane co-factor protein 1 (MCP-1) and
RANTES expression, probably via nuclear factor-kappa B
(NF-kB) in tubular epithelial cells.6,7 HGF also offers
protection in acute ischemic and inflammatory injuries by
its antiapoptotic and proangiogenic effects8,9 by attenuating
ischemia-induced cell death10 and ischemia- or toxic-induced
acute renal failure.11–14 In human critical limb ischemia, HGF
has been safely applied in phase I/early phase IIa, which
indicates its usefulness as a sole therapy.15
Gene therapy is now moving from experimental studies
into clinical applications,16–18 but gene transfer methodology
is one of the limiting steps. Viral vector gene transfer has
proved efficient but does not allow repetitive injection. In
addition, although the administration of naked plasmid DNA
or liposome formulated DNA is feasible, the levels of the
therapeutic protein obtained are too low. Recently, DNA
electrotransfer has greatly improved nonviral gene transfer
efficiency. Electrotransfer is a classic technique used in vitro
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that has been adapted to experimental in vivo gene therapy.
In vivo, electroporation shows consistently high levels of
gene expression for many genes19 and is normally applied
after intramuscular injection (20–23, reviewed in Andre´ and
Mir24). Our group previously reported that HGF gene
electrotransfer is effective to treat late stages of diabetic
nephropathy.25
Chronic allograft nephropathy (CAN) is a multifactorial
process that leads to late allograft loss in renal transplanta-
tion. The joint association of nonalloreactive factors, as cold
ischemia, plus allogenicity significantly increases cellular
infiltration at both early and late stages, aggravating the
progression of experimental CAN.26–28
Here we tested the hypothesis that HGF electrotransfer
provides protection against the inflammatory and fibrotic
processes that finally leads to the characteristic features
of CAN. As HGF electrotransfer allows up to 14 days increase
in endogenous HGF,25 preventive gene therapy was applied
following two distinct timings: before renal transplan-
tation for the early post-transplant cytoprotection from
ischemia–reperfusion injury, or at 8 and 10 weeks after
transplantation for the delayed prevention of chronic
mechanisms.
RESULTS
HGF in CAN
Ten out of 26 NoHGF rats did not survive the study period
(Figure 1) and died of renal insufficiency. The surviving rats
developed progressive proteinuria (Figure 2b) along the
follow-up with renal insufficiency from the 16th week
(Figure 2a).
Rat HGF plasma levels in this model of kidney transplant
were found lower than those in rats with two native kidneys
(Figure S1B) (week 16: 7.2971.68 ng/ml; week 32:
6.2071.80 ng/ml).25 The profile of plasma rat HGF level in
NoHGF rats decreased with the progression of CAN. Levels
were higher at 4 weeks and dropped afterwards (Figure 3),
reaching the lowest values at 24 weeks when CAN was already
established.
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Figure 1 | Survival. HGF-treated groups showed improved survival
with respect to the nontreated one. The two treated groups showed
lower mortality rates. Po0.05 NoHGF vs IniHGF and DelHGF;
Kaplan–Meier and log-rank methods.
ProtO (cv) sCr (cv) CrCl (cv)
No HGF 34.3±3.7 99±6 716±36
Initial HGF 21.7±3.1a 83±5a 808±38
Delayed HGF 20.2±2.2a 77±2a 821±28a
P 0.0019 0.0023 0.0500
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Figure 2 | Renal function. (a) Proteinuria (ProtO, mg/24 h), serum
creatinine (sCr, mmol/l), and creatinine clearance (CrCl, mmol/min)
values obtained throughout the follow-up were compacted using the
StatViews5 program (SAS Institute Inc.) in a single variable
(cv¼ compacted variable) and compared with analysis of variance.
aPo0.05 vs NoHGF group. Serum creatinine and proteinuria were
clearly reduced by HGF treatment. Renal insufficiency was present
only in the NoHGF group. (b) Monthly values of ProtO revealed that
NoHGF rats displayed progressive proteinuria along the follow-up
whereas treatment with HGF prevented this proteinuria, especially in
the DelHGF group.
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Figure 3 | Plasma rat HGF protein kinetics. Here, the NoHGF
group showed an initial rapid decrease in rat HGF plasma levels,
while in the IniHGF group these levels decreased slowly and
progressively. In the DelHGF group, plasma rat HGF increased after
treatment and reached the highest levels at the end of the study
compared with the other groups. Analysis of variance, Fisher’s test,
*P¼ 0.0025 NoHGF vs DelHGF.
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At 24 weeks, conventional histology (Table 1a, Figure 4)
revealed interstitial fibrosis, tubular atrophy, a considerable
percentage of sclerosed glomeruli as well as a high number
of interstitial a-smooth muscle actin (a-SMA) (Figure 4)
and tubular and glomerular connective tissue growth
factor (CTGF)-positive cells (Table 1b, Figure 4). In addi-
tion to these fibrotic changes, inflammation was also
present, with macrophages and T cells infiltrating kidneys.
This cell infiltration was already notable at 12 weeks
(Figure 5).
The reverse transcription-polymerase chain reaction
results showed that tissue expression of the rHGF gene did
not vary between 12 and 24 weeks (Table 3). As results were
expressed as many fold with respect to nontransplanted
healthy kidneys (data not shown), values o1 in NoHGF
samples indicate that rat HGF gene expression was reduced in
CAN. Tissue rHGF protein in NoHGF grafts was lower at the
end of the study than at 12 weeks, although differences did
not reach statistical significance.
Effect of initial treatment with hHGF gene therapy on CAN
Animals from the IniHGF group had a higher survival rate
than those from the NoHGF group. Interestingly, initial
treatment with HFG delayed death by 8 weeks, after which
time only four of the 16 rats died, from renal insufficiency
(Figure 1). Rats in the IniHGF group developed only slight
proteinuria or renal insufficiency (Figure 2).
Here, one single intervention with our gene therapy
approach allows high human HGF plasma levels (460 pg/ml
day 6; 90 pg/ml day 11) as previously shown.22
The profile of endogenous rat HGF plasma levels in the
IniHGF group during the first weeks did not drop as
dramatically as in the NoHGF group but continued
decreasing along time (Figure 3). The tissue expression of
rat HGF gene and rat HGF protein content was similar in the
IniHGF and NoHGF groups (Table 3).
At 24 weeks, the conventional histology showed neither
vasculopathy nor glomerulosclerosis in any of them and few
signs of both fibrosis and infiltrating cells (Table 1a, Figure 4).
Immunohistochemistry revealed a clear reduction in the
deposition of the fibrotic markers a-SMA and CTGF (Table
1b, Figure 4).
Effect of delayed treatment with hHGF gene therapy on CAN
The DelHGF group had a better survival rate than the
NoHGF group as only three out of 16 rats died from renal
insufficiency (Figure 1). Interestingly, there was no mort-
ality during the 8 weeks after HGF electrotransfer, similarly
to IniHGF group. Rats in the DelHGF group displayed
normal and stable renal function throughout the entire
follow-up, in a similar manner to the IniHGF group. Despite
no statistical difference, at 24 weeks, creatinine and
proteinuria were lower in the DelHGF than in the IniHGF
group (Figure 2).
Table 1 | Histology
NoHGF
IniHGF
DelHGF
8 weeks 12 weeks 24 weeks 24 weeks 12 weeks 24 weeks
(a) Conventional histology
Tublar atrophy 0.8970.20 1.8770.55 1.2570.37 0.8270.35 0.5070.35 0.5070.25
Interstitial fibrosis 0.8970.20 3.1270.37 2.6170.27 1.9570.29 1.5070.54a 1.5070.25b
Cellular infiltrate 1.5670.18 3.0070.35 1.8970.38 1.3270.34 1.2570.52a 0.9270.34
Tub-Int score 3.3370.50 8.0071.21 5.7570.98 4.0970.94 3.2571.33a 2.9270.82b
Vasculopathy 0.2270.15 0.2570.25 0.3670.22 0.0970.09 0.0070.00 0.0070.00
% Glomerulosclerosis 1.5170.51 2.2271.57 12.7773.79 2.3972.09b 0.9570.66 3.0571.54b
(b) Inmunohistochemistry
ED1+ 20.4474.62 8.6371.57 6.2671.68 8.7971.23a 6.3371.35
CD45RC+ 17.0673.36 3.2170.89 2.5970.76 5.2471.49a 2.2770.74
CD3+ 44.7713.3 13.4173.99 12.5670.66 10.274.30a 9.6171.37
a-SMA 12.0771.33 13.0373.62 4.2071.94b 3.4071.19a 4.2271.40b
CTGF
Tubuli 1.6270.69 2.070.47 0.5770.23b 0.7570.32 1.0070.27b
Glomeruli 3.5371.02 7.4771.21 2.1770.76b 4.1771.32 3.9470.79b
(a) Conventional histology: Tubular atrophy, interstitial cell infiltration, interstitial fibrosis and vasculopathy were evalued on H&E and PAS sections and semiquantitatively
graded (0: no abnormalities; +1: abnormalities affecting o1/3 of the sample; +2: between 1/3 and 2/3; +3: 42/3 of the sample). Tubulo-interstitial score=tubular
atrophy+interstitial cell infiltration+interstitial fibrosis. Glomerulosclerosis (%)=global sclerosed glomeruli/total glomeruli number.
Kruskall–Wallis; aat 12 weeks, Po0.05 vs NoHGF. bat 24 weeks, Po0.05 vs NoHGF.
(b) Immunohistochemistry. CD45RC+, CD3+, ED1+ cells infiltrating kidneys, a-SMA+ interstitial cells and CTGF+ cells in glomeruli were counted and expressed as mean7s.e.m.
of cells per field of view o per glomerulus (cells/FV or cells/glom at  400 magnification, X20 counted fields or glomeruli per kidney). Tubuli CTGF staining was
semiquantitatively scored from 0 to +4.
At 12 weeks, ED1+, CD45RC+, CD3+ and a-SMA+ immunostaining were lower in DelHGF group. At 24 weeks both treated groups showed lower a-SMA and CTGF
immunostaining.
H&E, hematoxylin and eosin; HGF, hepatocyte growth factor; PAS, periodic acid Schiff; a-SMA, a-smooth muscle actin; Tub-Int, tubulo-interstitial.
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Figure 4 | Representative photomicrographs. (a–f): 12-week grafts (a–c: NoHGF; d–f: DelHGF); (g–o): 24-week grafts (g–i: NoHGF; j–l: IniHGF;
m–o: DelHGF). a, d, g, j, m: periodic acid Schiff (original magnification  200); b, e, h, k, n: a-SMAþ (original magnification  400); c, f, i, l, o:
CTGF (original magnification  400). One month after treatment with HGF, kidneys showed better preserved structures and scarce signs of
fibrosis ((d, e, f) DelHGF vs (a, b, c) NoHGF). At 24 weeks this difference was more notable, especially in relation with glomerulosclerosis,
a-SMA, and CTGF deposition ((g, h, i) NoHGF vs (j, k, l) IniHGF, and (m, n, o) DelHGF). In DelHGF kidneys, a-SMA was observed only in vessel
smooth muscle cells.
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Two courses of gene electrotransfer effectively resulted in
detectable human HGF plasma levels at 12 weeks (DelHGF:
141799 pg/ml; NoHGF: 070 pg/ml, Po0.05).
In constrast to the NoHGF and IniHGF groups, endogen-
ous rat HGF plasma levels in the DelHGF group increased
significantly after human HGF electrotransfer (Figure 3a).
Thereafter, plasma rat HGF in this group experienced
a parallel decrease to the other two groups. At the end of
the follow-up, rat HGF gene expression and protein content
in DelHGF grafts were higher than in the other groups
(Table 3).
At 24 weeks (412 weeks after HGF treatment), micro-
scopic observation of DelHGF kidneys showed scarce
lesions in renal structures without vasculopathy, glomerulo-
sclerosis or fibrosis and only a few infiltrating cells (Table 1,
Figure 4).
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Figure 5 | Inflammatory markers at 12 weeks. (a–f) representative photomicrographs of ED1 (a, b: original magnification  400), CD3
(c, d: original magnification  400), and NF-kB (e, f: original magnification  400 and original magnification  1000). (a, c, and e): NoHGF
kidneys; (b, d and f): DelHGF kidneys. The nuclear factor NF-kB was localized in (e, arrowhead) nuclei and (e, arrow) cytoplasms of tubular
epithelial cells of NoHGF kidneys. (f, arrow) Treatment with HGF reduced NF-kB staining and confined it to the cytoplasm. In accordance
with this lack of NF-kB nuclei translocation, cell infiltration was notably reduced (b, d vs a, c) 1 month after HGF gene therapy. (g) Contingency
table for NF-kB location. For NF-kB staining location and evaluation, a contingency table was constructed and compared with w2 test.
All four NoHGF kidney samples have NF-kB positive staining, located in both the cytoplasm and nucleus. Contrarily, only two DelHGF
kidneys were positive for NF-kB, which was exclusively located in the cytoplasm, and there was no nucleus staining in any of these samples.
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Modulation of intermediate mechanisms of CAN
by HGF gene therapy
The characteristic histological features of CAN began to
develop between 8 and 12 weeks (Table 1). Histological
assessment of nontreated kidneys at 8 weeks showed no signs
of tubulo-interstitial, vascular, or glomerular damage and
only a small number of infiltrating cells. When assessed at 12
weeks, glomeruli and tubulo-interstitial structures were
already damaged with an important component of inflam-
matory interstitial cellular infiltrate and fibrosis (Table 1a,
Figures 4 and 5). In addition to interstitial infiltrate, the
inflammatory cytokines IL12b, TNF-a, and INF-g were
overexpressed at 12 weeks (Table 2).
In the DelHGF group, renal tissue 1 month after treatment
not only showed less interstitial fibrosis but a reduced
number of all kinds of infiltrating cells, and displayed similar
values to those observed at 8 weeks in nontreated kidneys
(Table 1, Figures 4 and 5). In parallel with the few infiltrating
cells, HGF-treated kidneys at 12 weeks had clearly less
expression of inflammatory cytokines than NoHGF kidneys
(Table 2). To further assess inflammatory mechanisms, we
evaluated NF-kB expression. In nontreated kidneys, NF-kB
p65 subunit was widely found in epithelial tubular cells
following both a nuclear and cytoplasmic pattern, wheras
there was only faint cytoplasmatic staining in DelHGF
kidneys and no nuclear staining (Figure 5). Differences were
also seen at mRNA level (RelA), although here there was no
statistical significance (Table 2, see Figure S1A).
At 12 weeks, hHGF gene electrotransfer reduced transform-
ing growth factor-b (TGF-b) expression while slightly
increased rHGF, all resulting in a greater HGF/TGF-b ratio
(Table 3). At this moment, glomerulosclerosis and CTGF-
positive cells in tubuli or in glomeruli did not differ between
treated and nontreated kidneys (Table 1b), which indicates
that at 12 weeks extracellular matrix deposition was moderate
and it was not modified by HGF treatment. In contrast, at 24
weeks, TGF-b expression (Table 3) was reduced in DelHGF
kidneys and CTGF deposition was observed only in NoHGF
grafts (Table 1b, Figure 4). In addition, a-SMA deposition was
already manifested at 12 weeks in nontreated kidneys and,
importantly, HGF treatment clearly reduced the number of a-
SMA-positive cells both at 12 and 24 weeks (Figure 4). Besides
this clear difference in fibrotic markers, there also exists
difference with respect to regeneration at 12 weeks. The PCNA
gene expression was reduced in the NoHGF group whereas it
was significantly increased in HGF-treated kidneys (Table 3).
DISCUSSION
We have shown that treatment with HGF modifies the
natural outcome of chronic allograft nephropathy. One of the
contributions of the present study is the innovative nonviral
intramuscular gene electrotransfer used rather than the
classical HGF protein supplement.29 Gene therapy appears
to be the alternative to avert the half-life handicap of protein
HGF.30 One single intervention with our gene therapy
approach allows high human HGF plasma levels up to 14
days22 and increases endogenous rat HGF plasma and tissue
levels.25 The normal creatinine kinase levels of our electro-
pored rats ruled out the possibility of muscle damage
indicating the safety of the in vivo electroporation.
As a physiological mediator of tissue repair, endogenous
HGF increases after ischemic insult or acute rejection31 and
decreases in chronic processes.1,32 In our CAN model, the
highest rat HGF plasma levels were found early after
transplantation, when the kidneys were still under the late
effects of acute ischemic-induced inflammatory processes.
A rapid decrease in plasma HGF was observed as renal
Table 2 | Proinflammatory mediators at 12 weeks
RelA IL-12b TNF-a INF-c
NoHGF 1.8770.48 17.2474.40 82.29720.19 2807105
DelHGF 1.1770.28 6.9572.04a 38.5372.73a 102722
The gene expression of NF-kB p65 subunit (RelA), interleukin-12b (IL-12b), tumor
necrosis factor-alpha (TNF-a) and interferon-gamma (INF-g) were quantified by RT-
real-time PCR on 12-week tissue samples and results expressed as ‘many fold’ with
respect to control healthy nontransplanted kidneys (see Figure S1A).
t-Test, aPo0.05 vs NoHGF.
RelA expression was 1.6 fold-reduced by HGF electrotransfer. The assessed
proinflammatory cytokines were over-expressed in all kidney allografts but this
expression was 2–3-fold reduced in treated kidneys.
Table 3 | Regeneration vs fibrosis
NoHGF
IniHGF
DelHGF
12 weeks 24 weeks 24 weeks 12 weeks 24 weeks
mRNA (fold/normal)
PCNA 0.4070.10 1.1470.25a
c-Met 0.3370.14 0.7270.14
HGF 0.0170.01 0.1370.02 0.1670.03 0.0570.03 0.2770.07b
TGF-b 6.6772.79 9.4372.84 9.7773.33 0.8570.61a 5.9271.10
HGF/TGF-b 0.0170.01 0.0370.01 0.0370.01 2.32 72.27a 0.1470.08
Protein (ng/mg Protein)
HGF 1.5070.20 1.6170.19 1.2070.17 2.1970.5 2.1370.27c
Rat PCNA (proliferation cellular nuclear antigen), c-Met (HGF-receptor), HGF and TGF-b mRNA expression was quantified by reverse transcription-real-time polymerase chain
reaction on 12-week tissue samples. HGF and TGF-b were also quantified at 24 weeks. Rat HGF protein was measured by ELISA on tissue samples.
ANOVA, aat 12 weeks Po0.05 vs NoHGF; bat 24 weeks Po0.05 vs NoHGF; cat 24 weeks Po0.05 vs IniHGF.
The expression of the profibrotic factor TGF-b was reduced early after HGF treatment, at 12 weeks, resulting in an increase of HGF/TGF-b, suggestive of regeneration. This is
confirmed by the PCNA expression, a cell proliferation marker, which was significantly increased in HGF-treated animals.
ELISA, enzyme-linked immunosorbent assay; HGF, hepatocyte growth factor; TGF-b, transforming growth factor.
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damage became apparent and, at 24 weeks, endogenous HGF
gene expression fell below normal values. The decrease in
HGF is closely related to the destruction of tubular epithelial
cells,33 so the chronic renal fibrosis and tubular atrophy
observed may, in part, account for the decrease in HGF. Thus,
the rationale of HGF supplementation to exert a therapeutic
action in CAN is justified.
The other novelty is the treatment delivery following two
distinct timing schedules, before transplantation for early
post-transplant cytoprotection of tubular cells during
ischemic injury, and delayed delivery for the prevention of
chronic mechanisms. The natural course of human CAN
begin as early as a few weeks after transplantation.34 Clinical
protocol biopsies at 4 months have detected a significant
number of stable allografts that histologically have character-
istic features of CAN.35 As protocol biopsies allow the
recognition of early affected kidneys, they offer the possibility
to initiate early treatment. We did not attempt to turn back
advanced CAN because the treatment of established nephro-
pathies with severe renal insufficiency, proteinuria, and
scarring is rarely successful. Instead, we applied preventive
treatment in an attempt to find a therapy with potential
clinical benefits.
The profile of cytokine expression in experimental CAN
has been well described.36,37 After the initial inflammatory
burst, a relative period of quiescence occurs. Thereafter a
progressive macrophage infiltration between 12 and 16 weeks
reappears with macrophage-associated products such as
TNF-a and INF-g. Simultaneously, functional and structural
chronic changes begin to manifest.37 When we performed
HGF gene electrotransfer just before transplant, we aimed to
diminish ischemia–reperfusion mechanisms and, effectively,
late renal protection was achieved. Some studies report the
potential mechanisms of early beneficial effect of HGF on
ischemic injury. Nakamura et al.8 and Jayasankar et al.9
demonstrated the cardioprotective effect of HGF by reducing
ischemia-induced angiogenesis and apoptosis. Arthur et al.5
showed that HGF reduced microscopic bowel inflammation,
which indicates that the beneficial effect of HGF is
attributable to a direct anti-inflammatory action. We have
previously shown in a model of renal warm ischemia that
HGF gene therapy prevents the early postischemic damage by
reducing apoptosis and inflammation and by fostering
regenerative processes at 1 week.23 Here, we show that the
treatment of initial ischemia–reperfusion injury with HGF
electrotransfer also offers late benefits on CAN.
Like initial treatment, delayed hHGF electrotransfer
effectively attenuated the development of CAN because in
addition to reduced mortality and better renal function,
chronic renal damage was notably diminished at 24 weeks.
Interestingly, glomeruloesclerosis, tubular atrophy, and
interstitial infiltrate did not differ between 24 and 12 weeks,
just after gene therapy, indicating that renal scarring had
already been arrested at 12 weeks by HGF-delayed treatment.
The exact mechanism by which this delayed HGF adminis-
tration counteracts the progression of CAN is a matter of
discussion. In concordance with current data, here we
abrogate for two nonexcluding hypotheses. On the one hand,
through the proregenerative effects of HGF, which acts in a
reciprocal manner to TGF-b, which favors the fibrotic
mechanisms,1–4,38 and, on the other, through its beneficial
effects on inflammatory injury.5–10,23
As early as 12 weeks, TGF-b, a-SMA, and tubular CTGF
were already enhanced in nontreated kidneys but no
glomerulosclerosis or vasculopathy were observed. Delayed
hHGF electrotransfer clearly decreased TGF-b, increased
HGF/TGF-b ratio and PCNA expression indicating that cell
regeneration has been activated. Simultaneously, the number
of transforming cells expressing a-SMA as well as CTGF was
reduced. Interestingly, this reduction was still present at 24
weeks. Transformation to a-SMAþ cells from tubular cells is
believed to be a central event in the progression of chronic
renal fibrosis8 as myofibroblast activation is a predictor of
renal disease progression. Therefore, it is reasonable to
conjecture that HGF preserved the tubular epithelial cell
phenotype by blocking epithelial-to-mesenchymal transition.
In addition to tubulo-interstitial fibrosis, glomerular CTGF
was also enhanced at 12 weeks in NoHGF kidneys, with a
further increase at 24 weeks in parallel to glomeruloesclerosis.
Again, we found a consistent therapeutic effect of HGF
because a downregulation of glomerular CTGF and sub-
sequent extracellular matrix deposition in glomeruli had
occurred, as reported in diabetic nephropathy.25
In addition to the antifibrotic effect, a novel action has
been attributed to HGF, the amelioration of renal interstitial
inflammation.6 Our results show that, at 12 weeks, delayed
HGF treatment inhibited inflammatory cell infiltration,
reducing macrophages, CD3þ , B- and T-cell lymphocytes,
and their related cytokines IL12, TNF-a, and IFN-g. Other
authors6,7 have reported this anti-inflammatory effects
showing that HGF directly suppresses proinflammatory
cytokine expression via NF-kB in tubular epithelial cells.
Our results also indicate that HGF reduces NF-kB activation
as it hindered its overexpression and its translocation to the
nuclei in tubular epithelial cells of treated kidneys. Mono-
nuclear cells are crucial sources of profibrotic molecules,
products that may alter the function of contractile mesangial
cells in the glomeruli, thereby causing the overproduction of
the mesangial matrix37 and also activating interstitial resident
fibroblasts, thus promoting epithelial-to-mesenchymal tran-
sition leading to renal scarring. Blockade of this cell
infiltration in the DelHGF group effectively controlled later
profibrotic mechanisms and these animals showed less
glomerulosclerosis and interstitial fibrosis, thereby resulting
in the attenuation of CAN. Despite the spontaneous
reduction of cell infiltration at 24 weeks, renal damage
progressed in NoHGF kidneys, indicating that the beneficial
effects of HGF also reside in the blockade of profibrotic
inflammatory-induced mechanisms.
In conclusion, here we show that HGF gene therapy is
consistently effective in the prevention of renal allograft
fibrosis. It could be said that this is especially true when
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administration is delayed until the onset of fibrogenic
mechanisms. Someone can argue that the difference could
be derived from two HGF courses vs one. However, the
rationale of the study was to cover two phenomena that differ
in time and in duration: one initial usually brief period, and a
later, longer, and undefined one. This amelioration is related,
at least in part, to the reduction of profibrotic inflammatory
processes. The opportunity offered by accurate clinical
follow-up or protocol biopsies to identify patients who
present incipient features of CAN allows a more personalized
treatment of this chronic kidney disease. Thus, the delayed
safety gene electrotransfer used here should be clinically more
applicable than a systematic pretransplant approach.
MATERIALS AND METHODS
Animals and renal transplantation
For renal transplantation, inbred male Lewis rats received a kidney
from Fischer rats (250 g BW, Charles River by Harlan UK Limited,
Bicester, UK) as previously described.26 Kidneys were preserved for
2.5 h in EuroCollins at 41C. Animals received a single daily dose of
5 mg/kg cyclosporine (Sandimmun Neoral, Novartis, Spain) by oral
gavage for 15 days. On day 7, right native nephrectomy was
performed. All the procedures and housing conditions were in
accordance with the Guidelines of the Committee on the Care and
Use of Laboratory Animals and Good Laboratory Practice.
Gene therapy
The HGF expression vector was constructed as previously
described.22 Rats were anesthetized and plasmid was injected in
SP1017 vehicle (200 ml/leg) into the tibialis anterior muscle as
previously described.22,23 As controls, NoHGF rats were injected
with an inactive plasmid in SP1017 vehicle (200 ml/leg). Afterward,
an electrical field was applied to the area around the injection.22,23,25
Eight pulses (20 ms, 2 Hz) were delivered at 175 V/cm. Using this
methodology, human HGF plasma levels arose for 12 days (460 pg/
ml day 6; 90 pg/ml day 11) and were overexpressed in renal tissue up
to 15 days after electroporation.22
Sham or therapeutic interventions were performed in a single
course, 3 or 4 days before kidney transplantation in initial treatment
or two courses in the delayed treatment group, at 8 and 10 weeks
after transplantation.
Plasma creatinine kinase levels (creatinine kinase¼ 81.17
13.5 U/l) measured in 10 rats randomly selected from all groups
were found among the normal range (22–198 U/l).
Study design and follow-up
Before transplantation and then monthly until the end of the study
at 24 weeks, rats were weighed and placed in metabolic cages for
24 h urine and tail-vein-blood collection. Urine and serum
creatinine (mmol/l) were determined by Jaffe’s reaction (Beckman
Instruments, Palo Alto, CA, USA), creatinine clearance (ml/min) by
standard formula, and proteinuria (mg/24 h) by Ponceau’s method
(Bayer Diagnostics). At the end of the study, the grafted kidney was
processed for histological and molecular studies.
Rats were divided into three groups: NoHGF: control group of
kidney transplant injected with an inactive plasmid (n¼ 26);
IniHGF: an initial single course of HGF gene therapy delivered
3–4 days before transplantation (n¼ 16); and DelHGF: two delayed
courses of HGF gene therapy delivered on weeks 8 and 10 post-
transplantation (n¼ 16). Additional animals (n¼ 8) included in the
nontreated group were killed at 8 weeks to assess the histological
progression of CAN. One month after gene therapy (3 months
post-transplantation), some animals from the NoHGF and DelHGF
groups (n¼ 4, each group) were killed to further study the early
mechanisms involved. The high number of animals included in the
NoHGF group corresponded to the elevated post-transplant
mortality.
Histology
Tissue sections (3–4mm) were stained with hematoxylin and eosin
and periodic acid Schiff methods. A pathologist, blind to the
treatment groups, examined all sections for glomerular, vascular,
and tubulo-interstitial lesions. For glomerulosclerosis quantification
(%), the global sclerosed glomeruli of each kidney section were
counted and divided by the total number. Tubular atrophy,
interstitial cell infiltration, interstitial fibrosis, and vasculopathy
were graded following a semiquantitative scale from 0 to þ 3 (0
denoted no abnormalities; þ 1, less than 1/3; þ 2, between 1/3 and
2/3; þ 3, more than 2/3 of the sample). A total tubulo-interstitial
score was obtained by the addition of the three individual tubulo-
interstitial parameters.
Immunohistochemistry
Representative tissue sections were immunostained using the
immunoperoxidase technique. As primary antibodies, we used
monoclonal mouse anti-rat CD45RC for T/B cells (Serotec), CD3
for T cells (Serotec, Bionova cientifica, Spain), ED1 for monocyte/
macrophage (Oxford Biomarketing, Kidlington, UK), MS-113 for a-
SMA (NeoMarkers, Lab Vision Ltd, UK), a rabbit polyclonal-IgG for
CTGF (Santa Cruz Biotechnology Inc., CA, USA), and rabbit
polyclonal anti-NF-kB p65 subunit (Abcam plc, Cambridge, UK).
Horse anti-rabbit (Vector Laboratories, Burlingame, CA, USA) and
anti-mouse (Pierce Biotechnology Inc., Cultek SL, Madrid, Spain)
IgG were used as secondary antibodies. Samples were revealed with
ABC-DAB and counterstained with hematoxylin. No primary
antibodies were used for negative controls.
Positive CD45RC, CD3, and ED1 cells infiltrating kidneys, a-
SMAþ interstitial cells, and CTGFþ cells in glomeruli were
counted and expressed as mean7s.e.m. of cells per field of view or
per glomerulus (cells/FV or cells/glom at  400 magnification, X20
counted fields or glomeruli per kidney). Tubuli CTGF staining was
semiquantitatively scored from 0 to þ 4. Positive staining of NF-kB
p65 was assessed in the cytoplasm and nucleus of tubular epithelial
cells.
Determination of human and rat HGF protein levels
Human plasma HGF was measured using a commercially available
ELISA kit (R&D Systems, Minneapolis, USA) as previously
described.25 Rat HGF was determined by a commercially available
ELISA kit (Institute of Immunology, Japan) in plasma samples
(ng/ml) and renal tissue extracts (ng/mg prot) as previously
described.23,25 Total protein concentration was measured by
Bradford’s method (BioRad Laboratories GmbH, Mu¨nchen,
Germany). The rat HGF antibody does not cross-react with human
HGF.39
Quantification of renal rat gene expression by reverse
transcription-real-time-polymerase chain reaction
Total RNA extraction and reverse transcription was performed as
previously described.26 Tissue cDNA HGF was amplified and
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quantified by RT-real time-PCR (ABI Prisms 7700, Applied
Biosystems) using the comparative CT method.
30 The primers and
probe (Table 4) to detect the target sequence of rat HGF were
designed and optimized following the manufacturer’s instructions.40
The PDAR (prevedeloped TaqMan assay reagents) methodology41
was used for rat PCNA, c-met, TGF-b, TNF-a, INF-g, IL-12b, RelA,
and 18S polymerase chain reactions starting from 1 ml of each cDNA
sample. Pooled values of healthy nontransplanted kidneys were used
as the reference value. Results were expressed as ‘many fold of the
unknown sample’ with respect to the reference value (arbitrary
units). No polymerase chain reaction products were detected using
reverse-transcribed negative controls as template.
Statistical analysis
Statistical analysis was performed using the StatViews5 program
(SAS Institute Inc., Barcelona, Spain). Survival was analyzed using
the Kaplan–Meier and log-rank methods. Quantitative data were
compared using analysis of variance – Scheffe’s test for more than
two groups and t-test for two groups. To compare groups for
proteinuria, serum creatinine, and creatinine clearance throughout
the follow-up, variables were compacted (cv¼ compacted variable)
and compared with analysis of variance. For histological data,
Kruskall–Wallis and Connover’s tests were used. For NF-kB staining
evaluation, a contingency table was constructed and compared with
w2 test. Po0.05 was considered statistically significant. Data are
presented as mean7s.e.m.
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